Search

Your search keyword '"Bertan, Claudia"' showing total 242 results

Search Constraints

Start Over You searched for: Author "Bertan, Claudia" Remove constraint Author: "Bertan, Claudia"
242 results on '"Bertan, Claudia"'

Search Results

1. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

2. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

4. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

5. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer

6. RNASEH2B loss and PARP inhibition in advanced prostate cancer

7. Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer

8. BCL2 expression is enriched in androgen receptor-negative advanced prostate cancer

10. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

11. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer

12. Erratum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer” [Eur Urol 2023;83(3):224–38]

13. Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

14. Data from HER3 Is an Actionable Target in Advanced Prostate Cancer

15. Figure S1 from HER3 Is an Actionable Target in Advanced Prostate Cancer

16. Supplementary Data from HER3 Is an Actionable Target in Advanced Prostate Cancer

17. Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

18. Supplementary Methods and Materials from miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation

19. Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

20. Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

21. Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

22. Supplementary Data 2 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

23. Supplementary Figure 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

24. Supplementary Data 4 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

25. Data from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

26. Figure S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

27. Supplementary Figure 3 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

28. Table S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

29. Figure S5 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

30. Supplementary legend from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

31. Supplementary Table 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

32. Supplementary Data 3 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

33. Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

34. Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

35. Legends supplementary figures/ tables from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

36. Supplementary Data from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

37. Data from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

38. Data from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

39. Tables from Characterizing CDK12-Mutated Prostate Cancers

40. Supplementary Data 1 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

41. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

42. Targeting radioresistance and replication fork stability in prostate cancer

43. HER3 Is an Actionable Target in Advanced Prostate Cancer

44. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA

45. Abstract CT161: A homologous recombination repair (HRR) functional assay to stratify patients with metastatic prostate cancer for PARP inhibitor treatment in the TOPARP-B clinical trial

46. Abstract LB035: B7-H3 as a therapeutic target in prostate cancer

48. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

49. Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).

50. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

Catalog

Books, media, physical & digital resources